- Home
- CYCCP
as 11-21-2024 4:00pm EST
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
| Founded: | N/A | Country: | United States |
| Employees: | 12 | City: | BERKELEY HEIGHTS |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | N/A |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | N/A | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Cyclacel Pharmaceuticals Inc. News
CYCCP Breaking Stock News: Dive into CYCCP Ticker-Specific Updates for Smart Investing
Simply Wall St.
6 days ago
Cyclacel Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations
GlobeNewswire
7 days ago
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds
GlobeNewswire
8 days ago
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds
Zacks
9 days ago
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q3 Loss
GlobeNewswire
9 days ago
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
GlobeNewswire
a month ago
Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule
GlobeNewswire
a month ago
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
GlobeNewswire
a month ago
Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
Compare CYCCP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CYCCP Cyclacel Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.